Nicotine-mecamylamine treatment for smoking cessation: The role of pre-cessation therapy.

Abstract

The nicotinic antagonist mecamylamine was evaluated in a randomized smoking cessation trial. Four groups of participants (n = 20 per group) received nicotine plus mecamylamine, nicotine alone, mecamylamine alone, or no drug for 4 weeks before cessation. After the quit-smoking date, all subjects received nicotine plus mecamylamine treatment for 6 weeks. Nicotine skin patches (21 mg/24 hr) and mecamylamine capsules (2.5-5.0 mg twice per day) were used. Precessation mecamylamine significantly prolonged the duration of continuous smoking abstinence; abstinence rates at the end of treatment were 47.5% with mecamylamine and 27.5% without mecamylamine. Nicotine + mecamylamine reduced ad lib smoking, smoking satisfaction, and craving more than either drug alone. Moreover, the orthostatic decrease in blood pressure caused by mecamylamine was offset by nicotine. Mecamylamine before smoking cessation may be an effective adjunct to nicotine patch therapy.

Cites (1)

1. Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers
   Benowitz, Neal L, Jacob III, Peyton · 1993 · Clinical Pharmacology and Therapeutics

Show all 1 references

Cited by (16)

1. Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
   Gonzales, David · 2006 · JAMA
2. Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
   Coe, Jotham W., Brooks, Paige R., Vetelino, Michael G., Wirtz, Michael C., Arnold, Eric P., Huang, Jianhua, Sands, Steven B., Davis, Thomas I., Lebel, Lorraine A., Fox, Carol B. et al. · 2005 · Journal of Medicinal Chemistry
3. Nicotine replacement therapy for smoking cessation
   Stead, Lindsay F, Perera, Rafael, Bullen, Chris, Mant, David, Lancaster, Tim · 2008 · Cochrane Database of Systematic Reviews
4. Rationale, pharmacology and clinical efficacy of partial agonists of α4β2 nACh receptors for smoking cessation
   Rollema, Hans, Coe, Jotham W., Chambers, Leslie K., Hurst, Raymond S., Stahl, Stephen M., Williams, Kathryn E. · 2007 · Trends in Pharmacological Sciences
5. Smoking Cessation With Varenicline, a Selective α4β2 Nicotinic Receptor Partial Agonist: Results From a 7-Week, Randomized, Placebo- and Bupropion-Controlled Trial With 1-Year Follow-up
   Nides, Mitchell · 2006 · Archives of Internal Medicine

See all 183